Tivic Health Systems is a commercial-phase bioelectronic medicine company focused on inflammation. Co. first product, ClearUP® Sinus Relief (ClearUP), is a patented handheld device that uses ultra-low electrical waves to relieve symptoms of sinus and nasal inflammation. ClearUP is a US FDA Class II and EU Class IIa medical device that has received three regulatory clearances: (US FDA 510(k) number K182025, US FDA De Novo number DEN200006 and EU CE Mark Certificate number CE 704687). ClearUP consistently gets high ratings from consumers across multiple sales platforms. The TIVC stock yearly return is shown above.
The yearly return on the TIVC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TIVC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|